View Report
June 18, 2024
Batch #HDGW23
Measured Result
21.70 mg
108.50% of label claim
Dragon Pharma
Dragon Pharma
Latest Laboratory Result
21.70 mg
June 18, 2024 · 108.50% of label claim
View
GW501516 20 mg
Product Information
Compound Details
Active Substance
Cardarine
PPARδ agonist (GW501516)
20 mg/tablet
Strength
20 mg/tablet
Package
100 Tablets
2,000 mg total labeled content
Form
Oral Tablet
Half-Life
16–24 Hours
Drug Class
PPARδ Agonist
Manufacturer
Dragon Pharma
$140.00
Shipping :
International
U.S. Domestic
Product Overview
GW501516 20 mg by Dragon Pharma
GW501516 20 mg is an oral cardarine tablet manufactured by Dragon Pharma and dosed at 20 mg per tablet in a 100-tablet package.
Cardarine Oral
GW501516 20 mg contains cardarine (GW501516), a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist. It is not a steroid or a selective androgen receptor modulator (SARM); it works by activating PPARδ, a nuclear hormone receptor that regulates genes involved in fatty acid oxidation, mitochondrial biogenesis, and energy expenditure. This mechanism causes skeletal muscle to preferentially use fat as an energy source over carbohydrates, which is the basis for its reported effects on endurance and fat loss.
Cardarine was originally developed in the 1990s by Ligand Pharmaceuticals and GlaxoSmithKline as a potential treatment for obesity, diabetes, dyslipidemia, and cardiovascular conditions. Early-phase human trials were conducted, but development was abandoned in 2007 after preclinical toxicology studies in rodents showed that cardarine caused cancer in multiple organs, including the liver, thyroid, stomach, tongue, and testes. In non-medical bodybuilding and endurance-sport contexts, it is commonly referenced for fat loss, enhanced endurance, and increased cardiovascular capacity, though such use falls outside approved indications and carries serious health risks.
Cardarine is not approved by the FDA for human use and is classified as a research chemical. It is prohibited by the World Anti-Doping Agency (WADA) under the category of metabolic modulators. Non-medical use for performance or physique enhancement is associated with the carcinogenicity observed in animal studies and is strongly cautioned against by regulatory and anti-doping authorities.
Key Benefits of GW501516 20 mg
- Activates PPARδ to shift muscle metabolism toward fat oxidation
- Commonly referenced for enhanced endurance and cardiovascular capacity
- Does not aromatize and is not a steroid or SARM
- Half-life of 16–24 hours for once-daily dosing
- 20 mg tablet strength for flexible dosing
Product Profile
Cardarine Profile
Cardarine (GW501516) is a potent, selective PPARδ agonist with a reported half-life of 16–24 hours, developed for metabolic disorders but abandoned due to carcinogenicity in animal studies.
Selective PPARδ Agonist
Cardarine binds to and activates PPARδ with high affinity (Kd approximately 1 nM) and greater than 1000-fold selectivity over PPARα and PPARγ. Upon activation, PPARδ recruits the coactivator PGC-1α and heterodimerizes with the retinoid X receptor (RXR), leading to transcription of genes involved in fatty acid oxidation and mitochondrial biogenesis in skeletal muscle.
The half-life of cardarine is commonly referenced as 16–24 hours in non-medical discussion, which supports once-daily dosing. It has no androgenic activity, does not bind the androgen receptor, and does not suppress the hypothalamic-pituitary-testicular axis.
Cardarine was investigated in early-phase human clinical trials for lipid and lipoprotein metabolism, but development was halted when rodent carcinogenicity studies demonstrated tumor formation across multiple organ systems. The available human safety data is considered insufficient to establish long-term safety.
Defining Characteristic
Metabolic Modulator, Not a SARM
Cardarine is a PPARδ agonist, not a SARM or steroid. It does not touch the androgen receptor and does not suppress testosterone. Its risk profile is separate and includes carcinogenicity in animal studies.
GW501516 20 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers multiple compounds commonly discussed in bodybuilding and endurance contexts. Cardarine's PPARδ agonist mechanism and metabolic focus contrast with anabolic steroids such as Anavar 50 or Winstrol 50, which act via the androgen receptor. It is also distinct from selective androgen receptor modulators (SARMs) such as MK 2866 or RAD 140, which do target the androgen receptor. Cardarine is frequently grouped with SARMs in retail marketing, but this is a commercial convention rather than a pharmacological classification.
The primary practical distinction is that cardarine is used for its reported metabolic and endurance effects, not for muscle-building via androgen receptor activation.
Laboratory Testing
GW501516 20 mg Lab Reports
Published laboratory reports for GW501516 20 mg are shown below with the test date, measured cardarine content, and percentage of the product's 20 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every tablet or production batch.
Dosage & Usage
GW501516 20 mg Dosage & Usage
The information below is provided for educational reference only. Cardarine is not approved for human use and is classified as a research chemical. Non-medical use falls outside approved indications and is associated with serious health risks.
Typical Dosage Ranges
No safe or effective dosage has been established for humans. In early-phase clinical trials, doses up to 10 mg per day were administered for up to 12 weeks. In non-medical bodybuilding and endurance-sport contexts, cardarine is commonly referenced in the range of 10–20 mg per day, taken orally, with 20 mg being a frequently referenced dose. These doses are based on anecdotal reports rather than controlled human data establishing safety.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Clinical trial (historical) | Up to 10 mg / day | Once daily |
| Bodybuilding (non-medical) | 10–20 mg / day | Once daily |
| Endurance (non-medical) | 10–20 mg / day | Once daily |
Stacking & Cycle Considerations
In non-medical contexts, cardarine is frequently referenced alongside other compounds in fat-loss or endurance-focused stacks. It is commonly discussed with MK 2866 (ostarine) or RAD 140, though it is not a SARM and does not share their mechanism of action. It is also referenced with GW501516 standalone for endurance and cardiovascular work. Because cardarine does not suppress testosterone, it is not typically associated with post-cycle therapy requirements, but its carcinogenicity risk in animal studies is a serious safety concern regardless of stacking.
Managing Side Effects
Cardarine does not aromatize and does not suppress endogenous testosterone production. Reported side effects in non-medical contexts are limited, but research on long-term human safety is lacking. The primary safety concern is carcinogenicity observed in rodent studies, which led to the abandonment of clinical development. No long-term human safety data exists to establish a safe use profile.
Post-Cycle Therapy (PCT)
Cardarine does not suppress the hypothalamic-pituitary-testicular axis and is not associated with the need for post-cycle therapy in the way anabolic steroids are. It has no androgenic activity and does not interfere with endogenous testosterone production.
Important
Individual Response Varies
Cardarine is not approved for human use. The information above is for educational reference and does not constitute medical advice. Non-medical use is strongly cautioned against.
Safety & Information
Cardarine Safety Information
Cardarine (GW501516) is not approved for human use. Clinical development was abandoned after rodent studies showed carcinogenicity across multiple organ systems.
Important Safety Information
Cardarine is a research chemical with no approved human indication. It is prohibited by WADA and is not legally permitted in medications or supplements in the United States. The FDA has issued warning letters to companies selling cardarine, emphasizing that it is not safe for human consumption.
Important
Non-Medical Use
Cardarine has no approved human indication. Non-medical use falls outside approved indications and carries serious health risks. Product strength and laboratory verification do not establish safety for human consumption.
Potential Adverse Effects
Cancer risk: Rodent carcinogenicity studies demonstrated tumor formation in multiple organs, including liver, thyroid, stomach, tongue, and testes. This is the reason clinical development was halted.
Unknown long-term effects: Human safety data is insufficient to assess long-term risks due to the small number of short-duration clinical trials conducted.
Potential interactions: As a PPARδ agonist, cardarine may interact with medications affecting glucose metabolism, coagulation, and liver-metabolized drugs, though comprehensive interaction data is unavailable.
Conditions Requiring Medical Evaluation
Given the carcinogenicity observed in animal studies, any consideration of cardarine exposure warrants comprehensive medical evaluation. Individuals with a history of cancer or risk factors for cancer, liver disease, or cardiovascular conditions are at heightened theoretical risk. Athletes subject to drug testing should be aware that cardarine is detectable and prohibited.
Monitoring During Therapy
There is no established monitoring protocol for non-medical cardarine use. For any human exposure, liver function tests, lipid panel, and general health assessment should be considered by a qualified healthcare professional. No safe monitoring parameters have been established because human safety data is inadequate.
Product Care
Storage & Handling
Store in a cool, dry place away from direct light and moisture. Keep the product in its original packaging and out of the reach of children. This product is not for human consumption.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
GW501516 20 mg is supplied through the Dragon Pharma distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic
3–5 business days
International
10–15 business days
Order Processing
24–48 business hours
Tracking
Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your GW501516 20 mg product, cross-check the security features on the packaging against Dragon Pharma's official presentation. Batch-linked lab proof and original packaging help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
GW501516 20 mg Storage
Proper storage conditions help preserve tablet integrity and overall product stability throughout shelf life.
Recommended Conditions
Store in a cool, dry place away from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the tablets.
Keep the tablets in their original packaging until use. Do not use if the packaging appears compromised or if the tablets show signs of degradation such as discoloration or crumbling.
Keep out of reach of children. This product is not for human consumption.
Quick Reference
Do & Don't
- Do store in a cool, dry place
- Do keep in original packaging
- Do inspect tablets before use
- Don't expose to direct sunlight
- Don't store in humid environments
- Don't use if tablets appear abnormal
Frequently Asked Questions
GW501516 20 mg FAQ
Answers to common questions about GW501516 20 mg, cardarine, PPARδ activation, dosing, and safety.
What is GW501516 20 mg used for?
GW501516 20 mg contains cardarine, a PPARδ agonist. It has no approved medical use. In non-medical bodybuilding and endurance-sport contexts, it is commonly referenced for fat loss and enhanced endurance, though such use falls outside approved indications and carries serious health risks.
How often should GW501516 20 mg be taken?
Cardarine has a half-life commonly referenced as 16–24 hours, which supports once-daily dosing. In non-medical contexts, it is typically referenced as being taken once daily at 10–20 mg.
Does GW501516 20 mg require PCT?
No. Cardarine is a PPARδ agonist with no androgenic activity. It does not bind the androgen receptor and does not suppress the hypothalamic-pituitary-testicular axis, so post-cycle therapy is not associated with its use.
What does cardarine do?
Cardarine activates PPARδ, a nuclear receptor that regulates genes involved in fatty acid oxidation and mitochondrial biogenesis in skeletal muscle. This shifts muscle metabolism toward using fat as an energy source, which is the basis for its reported endurance and fat-loss effects. It is not a steroid or SARM.
How long does GW501516 take to work?
In non-medical contexts, users often report noticeable endurance and fat-loss effects within the first 1–2 weeks of use. However, these reports are anecdotal and no controlled human trials have established efficacy or onset time for performance outcomes.
Is cardarine a SARM?
No. Cardarine is a PPARδ agonist, not a selective androgen receptor modulator. It is frequently grouped with SARMs in retail marketing, but this is a commercial convention rather than a pharmacological classification.
What is the difference between cardarine and ostarine?
Cardarine is a PPARδ agonist that modulates fat metabolism and does not touch the androgen receptor. MK 2866 (ostarine) is a SARM that does bind the androgen receptor and can suppress testosterone. They have completely different mechanisms of action.
What is the difference between cardarine and RAD 140?
Cardarine is a PPARδ agonist with no androgenic activity. RAD 140 is a SARM that acts via the androgen receptor and is used for muscle-building. They are mechanistically unrelated compounds.
Is 20 mg of cardarine a lot?
Clinical trials used doses up to 10 mg per day for up to 12 weeks. In non-medical contexts, 20 mg per day is a commonly referenced dose, but no safe or effective human dose has been established. GW501516 20 mg is labeled at 20 mg per tablet.
What strength is GW501516 20 mg?
GW501516 20 mg is labeled at 20 mg of cardarine per tablet. It is supplied in a 100-tablet package, giving 2,000 mg of total labeled cardarine content.
Is GW501516 20 mg lab tested?
Yes. A published laboratory report dated June 18, 2024 measured GW501516 20 mg at 21.70 mg per tablet, equivalent to 108.50% of its 20 mg label claim. Complete reports can be viewed in the Lab Reports tab.
Is cardarine approved for human use?
No. Cardarine is not approved by the FDA for human use and is classified as a research chemical. It is prohibited by WADA and is not legally permitted in medications or supplements in the United States.
Related Offers
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Testosterone Cypionate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable (MCT Oil)
Estimated Half-Life Approximately 8 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
$53.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Testosterone Enanthate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable (MCT Oil)
Estimated Half-Life Approximately 4.5–7 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
$46.00
Lab Tested
Domestic & International
Buy 5+ for $56.73 and save $21.35
Dragon Pharma, Europe
Product Information
Compound Details
Active Substance
Tadalafil Citrate
Long-acting PDE5 inhibitor
20 mg/tablet
Strength
20 mg/tablet
Package
100 Tablets
2,000 mg total labeled content
Form
Oral Tablet
Drug Class
PDE5 Inhibitor
Manufacturer
Dragon Pharma
Half-Life
Approximately 17.5 Hours
$61.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information
Compound Details
Active Substance
Clenbuterol Hydrochloride
Beta-2 adrenergic agonist
40 mcg/tablet
Strength
40 mcg/tablet
Package
100 Tablets
4,000 mcg total labeled content
Form
Oral Tablet
Half-Life
Approximately 35 Hours
Drug Class
Beta-2 Agonist
Manufacturer
Dragon Pharma
$44.00